Are you on the lookout for some big returns? If you are, then read on because listed below are three ASX 200 shares that have been tipped to rise strongly by brokers.
Here's what they are saying about these buy-rated stocks:
Morgans sees a lot of value in this network as a service provider and tipped it as an ASX 200 share to buy last week.
The broker believes Megaport is well-placed to benefit from the artificial intelligence megatrend. It recently explained:
Megaport is a global cloud connection network and the leading Network as a Service provider. It operates the largest data centre connection business in the world, connecting to 850 data centres through a fully automated, on-demand telco network. We think it is uniquely placed to help business move data globally and benefit from the growth of data related to both cloud computing and AI.
Morgans has an add rating and $12.50 price target on its shares. This implies potential upside of 66% for investors over the next 12 months.
Analysts at Bell Potter think that Premier Investments could be an ASX 200 share to buy following a recent pullback.
While somewhat disappointed with last week's trading update, it remains positive and sees plenty of value in the Smiggle and Peter Alexander owner's shares. It said:
We remain positive on PMV's post demerger business, with higher margin Smiggle/PA, domestic:offshore exposure of 70:30 (BPe) growing at ~11% (BPe, FY26e), in addition to a ~26% ownership in Breville Group (BRG), property assets valued at cost and a strong cash balance (~$327m, BPe).
Bell Potter has a buy rating and $34.00 price target on its shares. This suggests that upside of 20% is possible from current levels.
Goldman Sachs has just initiated coverage on ResMed and named it as an ASX 200 share to buy.
The broker believes the sleep disorder treatment company is destined to deliver strong growth through to FY 2030. In light of this, it feels that its shares are being undervalued by the market. It said:
Our Buy recommendation on RMD is premised on (1) Ongoing robust new patient growth for CPAP therapy despite the market entry of GLP-1 drugs to treat OSA, (2) Further RMD market share gains, building on its #1 global market position, (3) Expansion of the OSA market in regions outside of the US. We believe the stock's current trading multiple is unjustified based on its growth outlook.
Goldman has a buy rating and $48.90 price target on ResMed's shares. This implies potential upside of approximately 28% for investors over the next 12 months.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.